, Tracking Stock Market Picks
Enter Symbol:

up 1,434.45 %

PHARMASSET INC. (VRUS) rated Outperform by Cowen & Co

Posted on: Wednesday,  Oct 29, 2008  9:25 AM ET by Cowen & Co

Cowen & Co rated Outperform PHARMASSET INC. (NASDAQ: VRUS) on 10/29/2008, when the stock price was $8.93. Since
then, PHARMASSET INC. has gained 1434.45% as of 01/17/2012's recent price of $136.95.
If you would have followed this Cowen & Co's recommendation on VRUS, you would have gained 1434.45% of your investment in 1175 days.

Pharmasset, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of drugs to treat viral infections. It focuses on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV).

Cowen and Company’s culture is rooted in the traditions of the research boutiques that once dominated the investment research landscape. Our primary focus is on two products: 1. Proprietary information flow, and 2. Good investment ideas We achieve the first objective with a combination of extensive primary research work, organized survey activity, and access to industry experts (i.e., opinion leaders in medicine, technology, and consumer industries). We believe that the best investment idea is a “Correct Non-Consensus Conclusion,” and a considerable amount of our energy is devoted to this pursuit. We spend as little time as possible on traditional maintenance research products.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/29/2008 9:25 AM Buy
as of 12/24/2008
1 Week up  0.97 %
1 Month up  4.70 %
3 Months down  -28.75 %
1 YTD down  -28.75 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy